Raymond James Financial’s CytomX Therapeutics CTMX Stock Holding History
Bought
Maintained
Sold
Other funds holding CTMX
KCM
Raymond James Financial's CTMX Position: Q3 2026 in Review
Raymond James Financial reduced its CytomX Therapeutics (CTMX) stake by 3.4% in Q3 2026, selling an estimated $55.3K and leaving 467,638 shares worth $1.27M. The position accounts for ﹤0.01% of the portfolio, ranked #3860.
Raymond James Financial first reported a position in CTMX in Q2 2025 and has held it in 6 quarters since. The position peaked at $1.82M in Q2 2026. 194 funds tracked by Wall St. Rank hold CTMX as of Q3 2026.
- Raymond James Financial held 467,638 shares of CytomX Therapeutics worth $1.27M as of Q3 2026.
- Raymond James Financial sold 16,584 CytomX Therapeutics shares in Q3 2026, an estimated $55.3K.
- CytomX Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #3860 holding.
- Raymond James Financial first reported a position in CytomX Therapeutics in Q2 2025 and has held it in 6 quarters since.
- Raymond James Financial's CytomX Therapeutics position peaked at $1.82M in Q2 2026.
- 194 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2026.
Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.